1. "Solid Tumor Oncology Division"
Formats
  1. Journal Article (10831)
  2. Meeting Abstract (9435)
  3. Review (542)
  4. Book Section (410)
  5. Editorial (324)
  6. Guidelines (154)
  7. Correspondence (115)
  8. Conference Paper (106)
  9. Research Letter (60)
  10. Miscellaneous (53)
  11. Book Whole (27)
Groups
  1. Solid Tumor Oncology Division (22057)
  2. Department of Medicine (22035)
  3. GSK Faculty (5880)
  4. Genitourinary Oncology Service (5608)
  5. Survivorship Research (5184)
  6. Gastrointestinal Oncology Service (4640)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. Clifford Hudis (905)
  4. Jedd Wolchok (905)
  5. Mark Kris (869)
  6. Leonard Saltz (790)

More People

Years
  1. 2025 (445)
  2. 2024 (1382)
  3. 2023 (1380)
  4. 2022 (1573)
  5. 2021 (1517)
  6. 2020 (1535)

More Years

Publications
  1. Journal of Clinical Oncology (5227)
  2. Annals of Oncology (1294)
  3. Cancer Research (1012)
  4. Clinical Cancer Research (768)
  5. Journal of Thoracic Oncology (530)
  6. Gynecologic Oncology (441)

More Publications

Publishers
  1. American Society of Clinical Oncology (5507)
  2. Elsevier Inc. (2651)
  3. American Association for Cancer Research (2316)
  4. Oxford University Press (1810)
  5. Nature Publishing Group (1026)
  6. Springer (975)

More Publishers

Results (22057)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Genomic characterization of rectal cancer and molecular determinants of response to neoadjuvant chemoradiotherapy
    Meeting Abstract

    Chatila, W. K.; Marco, M.; Qu, X.; Walch, H. S.; Luthra, A.; Chen, C. T.; Kundra, R.; Schultz, N.; Yaeger, R.; Smith, J. J.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • A phase I study to evaluate the safety and tolerability of AB680 combination therapy in participants with gastrointestinal malignancies
    Meeting Abstract

    Bendell, J. C.; Manji, G. A.; Pant, S.; Lai, D. W.; Colabella, J.; Berry, W.; Paoloni, M. C.; Grossman, W. J.; O'Reilly, E. M.
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • A phase 1 dose escalation study of PRS-343, a HER2/4-1bb bispecific molecule, in patients with HER2-positive malignancies
    Meeting Abstract

    Piha-Paul, S.; Bendell, J.; Tolcher, A.; Hurvitz, S.; Patnaik, A.; Shroff, R.; Pohlmann, P.; Zettl, M.; Hahn, N.; Krishnamurthy, A.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • Construction of the immune landscape of durable response to checkpoint blockade therapy by integrating publicly available datasets
    Meeting Abstract

    Rudqvist, N. P.; Zappasodi, R.; Wells, D.; Thorsson, V.; Cogdill, A.; Monette, A.; Najjar, Y.; Sweis, R.; Wennerberg, E.; Bommareddy, P.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • Evaluation of preanalytic variables in liquid biopsy tests for prostate cancer: Specimen acquisition and patient context factors that impact results
    Meeting Abstract

    Tsui, D.; Barnett, E. S.; Bramlet, K.; Schonhoft, J.; Rizzi, R.; Scher, H. I.
    Clinical Cancer Research (2020)

    Fulltext@MSK | Save
  • L1CAM defines the regenerative origin of metastasis initiating cells in colorectal cancer
    Meeting Abstract

    Ganesh, K.; Basnet, H.; Kaygusuz, Y.; Laughney, A.; He, L.; Sharma, R.; O'Rourke, K.; Reuter, V.; Huang, Y. H.; Masilionis, I.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • MSI detection in plasma cfDNA: MSI as a marker of disease burden
    Meeting Abstract

    Srinivasan, P.; Latham, A.; Patel, Z.; Ziegler, J.; Hasan, M.; Patel, J. A.; Johnson, I.; Shah, R.; Meng, F.; Jing, X.; more...
    Clinical Cancer Research (2020)

    Fulltext@MSK | Save
  • Validation and clinical implementation of MSK-ACCESS, an ultra-deep sequencing assay for noninvasive somatic mutation profiling
    Meeting Abstract

    Brannon, A. R.; Jayakumaran, G.; Diosdado, M.; Hu, Y.; Razumova, A.; Meng, F.; Lebow, E.; Patel, J.; Johnson, I.; Srinivasan, P.; more...
    Clinical Cancer Research (2020)

    Fulltext@MSK | Save
  • Neratinib + trastuzumab + fulvestrant for HER2-mutant, hormone receptor-positive, metastatic breast cancer: Updated results from the phase 2 SUMMIT 'basket' trial
    Meeting Abstract

    Wildiers, H.; Boni, V.; Saura, C.; Oliveira, M.; Jhaveri, K.; Won, H.; Bidard, F. C.; Brufsky, A. M.; Burkard, M. E.; Cervantes, A.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • TBCRC 033: A randomized phase II study of adjuvant trastuzumab emtansine (T-DM1) vs paclitaxel (T) in combination with trastuzumab (H) for stage I HER2-positive breast cancer (BC) (ATEMPT)
    Meeting Abstract

    Tolaney, S. M.; Trippa, L.; Barry, W.; Hu, J.; Dang, C.; Yardley, D.; Isakoff, S.; Valero, V.; Faggen, M.; Mulvey, T.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save